Notification of Interim Results

RNS Number : 0361P

ReNeuron Group plc

14 November 2016

 

14 November 2016

AIM: RENE

ReNeuron Group plc

("ReNeuron" or "the Company")

Notification of Interim Results

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, intends to announce its interim results for the six months ended 30 September 2016 on Monday 5 December 2016.

The Company also expects to announce initial three month follow-up data from the PISCES II clinical trial of its CTX cell therapy candidate for stroke disability on the same day.

A meeting for analysts will be held at 9.00am on the morning of 5 December 2016 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 9.00am on the day of the results:

http://vm.buchanan.uk.com/2016/reneuron051216/registration.htm

A recording of the presentation will be made available on ReNeuron's and Buchanan's websites, www.reneuron.com and www.buchanan.uk.com

Enquiries:

ReNeuron	[phone]
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan	[phone]
Mark Court, Sophie Cowles, Stephanie Watson
Stifel Nicolaus Europe Limited	[phone]
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.   

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

 

END

 

 

NOREANFDFAKKFFF